Feed BCRX
BC

BioCryst Pharmaceuticals, Inc.

BCRX · NASDAQ

$8.68 +0.40% (+$0.04)
1M -10.33%
Market Cap $2.21B
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$12.94

49.1% upside

Trenutna cena

$8.68

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BCRX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
91 /100
Cheap
P/S 2.35x
P/FCF 6.18x
P/E N/A
Growth
100 /100
Growing
Rev. growth 47.82%
EPS growth N/A
FCF growth N/A
Profitability
38 /100
Moderate
Gross margin 23.52%
Net margin 40.90%
Op. margin 33.29%
Quality
21 /100
Poor
ROIC 89.78%
ROA 68.96%
Asset turnover 1.69x
Debt
43 /100
Moderate
Current ratio 2.32x
Int. coverage -4.10x
Debt/Equity N/A
Stability
29 /100
Unstable
Beta 0.56x
Rev. volatility 38.09%
EPS volatility 200.31%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BCRX
Online

O podjetju

BioCryst Pharmaceuticals, Inc. (BCRX) is an American biotechnology company specializing in research, development, and commercialization of therapeutic compounds for the treatment of rare and serious diseases. With a primary focus on developing drugs for rare metabolic disorders and infections, BioCryst Pharmaceuticals leads innovations in therapeutic approaches. The company is known for its advanced technologies and successful clinical trials, which strengthen investor confidence. BioCryst Pharmaceuticals, Inc. (BCRX) shares could be suitable for investors seeking opportunities in the biotechnology sector with an emphasis on drug development for rare diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Charles K. Gayer

Employees

435

Headquarters

Durham

Prihajajoči dogodki

02 NOV.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.